Loading
companiesCompany
Frantz Viral Therapeutics
Frantz Viral Therapeutics is a US-based biotechnology company that leads 2 cancer trials in OnCo, testing self-administered artesunate inserts and ointment for HPV-related pre-cancers in vaginal cancer and vulvar cancer.
Also called: Frantz Viral Therapeutics, LLC
Overview
Frantz Viral Therapeutics develops non-surgical, self-administered artesunate treatments for HPV-induced pre-cancers and cancers of the cervix, vulva, anus and oropharynx, delivered as vaginal inserts, suppositories or ointment. It is a collaboration between Georgetown University Medical Center and Frantz Medical Group. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT04098744 (phase 2, Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN...) and NCT06075264 (phase 2, Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous I...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Similar pages
- JournalJournal of gynecologic oncology
Shares Vaginal cancer, Vulvar cancer.
- TrialEvaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Shares Vaginal cancer, Vulvar cancer.
- CompanyShanghai Bovax Biotechnology
Shares Vaginal cancer, Vulvar cancer.
- CancerHPV-associated vulvar squamous cell carcinoma
Shares Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3), Vulvar cancer.
- JournalInternational journal of gynecological cancer
Shares Vaginal cancer, Vulvar cancer.
- TreatmentNonavalent HPV vaccine
Shares Vaginal cancer, Vulvar cancer.
- TermHPV-positive (p16) head and neck cancer
Shares Vaginal cancer, Vulvar cancer.